This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Skapek, S. X. Articles by Grier, H. E. Search for Related Content PubMed PubMed Citation Articles by Skapek, S. X. Articles by Grier, H. E.

Vinblastine and Methotrexate for Desmoid Fibromatosis in Children: Results of a Pediatric Oncology Group Phase II Trial

Stephen X. Skapek, William S. Ferguson, Linda Granowetter, Meenakshi Devidas, Antonio R. Perez-Atayde, Louis P. Dehner, Fredric A. Hoffer, Roseanne Speights, Mark C. Gebhardt, Gary V. Dahl, Holcombe E. Grier

From the Departments of Oncology and Radiological Sciences, St Jude Children's Research Hospital, Memphis, TN; Department of Hematology/Oncology, Cardinal Glennon Children's Hospital; Lauren V. Ackerman Laboratory of Surgical Pathology, St Louis Children’s Hospital, Washington University Medical Center, St Louis, MO; Department of Pediatric Oncology, Columbia Presbyterian College of Physicians and Surgeons, New York, NY; The Children's Oncology Group Data Center and Department of Epidemiology and Health Policy Research, University of Florida, Gainesville, FL; Departments of Pathology, Orthopedic Surgery, and Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and the Children's Hospital, Boston, MA; and Department of Pediatric Hematology/Oncology, Stanford University Medical Center, Palo Alto, CA

Address reprint requests to Stephen X. Skapek, MD, St Jude Children's Research Hospital, 332 N Lauderdale St, Memphis, TN 38105; e-mail: steve.skapek{at}stjude.org

Purpose: To determine the efficacy and safety of using vinblastine (Vbl) and methotrexate (Mtx) in children with desmoid-type fibromatosis that is recurrent or not amenable to treatment with radiation or surgery.

Patients and Methods: A phase II study was conducted within the Pediatric Oncology Group. Patients were treated using Vbl (5 mg/m²/dose) and Mtx (30 mg/m²/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks. Response was assessed by bidimensional measurements of tumor on axial imaging (magnetic resonance imaging or computed tomography).

Results: Over 35 months, 28 patients were enrolled; 27 were eligible, and 26 were assessable for response. A measurable response was documented in eight patients (31%), and 10 patients had stable disease documented as the best response to treatment. Eighteen patients had disease progression at a median time of 9.1 months. Eight patients remain free of disease progression at a median of 43.4 months from study entry. Nine patients reported no to moderate toxicity. Neutropenia was the most common toxicity (n = 22) and the most common grade 4 toxicity (n = 5). Anemia, nausea, vomiting, and elevations in hepatic transaminases were also common and were reversible with interruption of chemotherapy.

Conclusion: Vbl and Mtx are well tolerated in children with desmoid-type fibromatosis. Furthermore, this combination can promote tumor regression or block tumor growth in most children.

Supported by National Institutes of Health Grants No. CA098543-02 (R.S.) and CA29139 (M.D.) and by the American Lebanese Syrian Associated Charities (S.X.S., F.A.H., R.S.).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				H F A Vasen, G Moslein, A Alonso, S Aretz, I Bernstein, L Bertario, I Blanco, S Bulow, J Burn, G Capella, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP) Gut, May 1, 2008; 57(5): 704 - 713. [Abstract] [Full Text] [PDF]